Inventaire - your friends and communities are your best library - Inventaire

mTOR kinase structure, mechanism and regulation

author

Joseph D Koos

published in: Nature

date of publication: 2013-05-01

language: English

main subject: pp-242, pi-103, torin 2

Cites articles 53

Date

Title

Authors

2011-05-01

Briefly bound to activate: transient binding of a second catalytic magnesium activates the structure and dynamics of CDK2 kinase for catalysis

Matthew Young
2011-04

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

Bryan T. Hennessy
2011-06-01

The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling

David M. Sabatini, Nathanael Gray
2011-02-15

Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer

David M. Sabatini, Nathanael Gray
2010-12-15

mTOR: from growth signal integration to cancer, diabetes and ageing

Alejo Efeyan, David M. Sabatini
2010-03-26

Shaping Development of Autophagy Inhibitors with the Structure of the Lipid Kinase Vps34
2010-02

PHENIX: a comprehensive Python-based system for macromolecular structure solution

Nathaniel Echols, Jane Shelby Richardson, David C. Richardson, Li-Wei Hung, Paul D. Adams, Thomas C. Terwilliger, Randy Read, Ralf W Grosse-Kunstleve, Pavel V Afonine, Vincent B Chen, Jeffrey J Headd, Gary J Kapral, Nigel W Moriarty, Gábor Bunkóczi, Airlie McCoy, Peter H. Zwart
2009-12-20

Crystal structure of DNA-PKcs reveals a large open-ring cradle comprised of HEAT repeats

Tom Blundell, Dimitri Y Chirgadze
2009-09-02

Common mechanisms of PIKK regulation
2009-05

Molecular mechanisms of mTOR-mediated translational control
2009-02-18

Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy
2009-03-01

A conserved docking surface on calcineurin mediates interaction with substrates and immunosuppressants

Martha Cyert
2009-03-19

Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein
2008-10-12

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases

Beatriz González, Tamim M Nazif, Roger L. Williams, Zachary A Knight
2008-05-22

The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1

David M. Sabatini
2008-08

Regulation of TORC1 by Rag GTPases in nutrient response
2008-09-23

Isolation of hyperactive mutants of mammalian target of rapamycin

Mizushima Noboru
2008-04-01

A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis
2007-08-24

PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex

Carol MacKintosh, Christopher G. Proud
2007-07-13

The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1

Kenta Hara
2007-03-01

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

David M. Sabatini, Eric Spooner
2007-02-20

Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells
2006-05-19

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

Robbie Loewith, Andras Balla, Zachary A Knight, William A Weiss, Tamas Balla, David Stokoe
2006-05-25

Ras, PI(3)K and mTOR signalling controls tumour cell growth
2006-08-21

Caffeine targets TOR complex I and provides evidence for a regulatory link between the FRB and kinase domains of Tor1p.
2005-04-26

Rheb binds and regulates the mTOR kinase
2004-11

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Robbie Loewith, Estela Jacinto
2004-07-27

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

Hediye Erdjument-Bromage, Paul Tempst, Do-Hyung Kim, David M. Sabatini
2004-09-10

Regulation of protein kinases; controlling activity through activation segment conformation
2004-07-01

An activated mTOR mutant supports growth factor-independent, nutrient-dependent cell survival
2003-10-23

Generation, representation and flow of phase information in structure determination: recent developments in and around SHARP 2.0
2003-04-28

LST8 negatively regulates amino acid biosynthesis as a component of the TOR pathway

Article - wd:Q27677954

Welcome to Inventaire

the library of your friends and communities

you are offline